140 related articles for article (PubMed ID: 21114695)
1. The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma.
Davidson B
Cytopathology; 2011 Feb; 22(1):5-21. PubMed ID: 21114695
[TBL] [Abstract][Full Text] [Related]
2. New diagnostic and molecular characteristics of malignant mesothelioma.
Davidson B
Ultrastruct Pathol; 2008; 32(6):227-40. PubMed ID: 19117264
[TBL] [Abstract][Full Text] [Related]
3. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
Ordóñez NG
Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
5. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
6. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
7. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Takeshima Y; Amatya VJ; Kushitani K; Inai K
Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
[TBL] [Abstract][Full Text] [Related]
8. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
9. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
Davidson B; Baekelandt M; Shih IeM
Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
[TBL] [Abstract][Full Text] [Related]
10. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K; Nymoen DA; Reich R; Davidson B
Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
[TBL] [Abstract][Full Text] [Related]
11. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
12. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
13. Value of immunohistochemistry in confirming undifferentiated ovarian carcinomas.
Georgescu CV; Florescu M; Simionescu C
Rom J Morphol Embryol; 1999-2004; 45():133-42. PubMed ID: 15847387
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary.
Silcocks PB; Herbert A; Wright DH
J Pathol; 1986 Jun; 149(2):133-41. PubMed ID: 2426430
[TBL] [Abstract][Full Text] [Related]
16. Huge peritoneal malignant mesothelioma mimicking primary ovarian carcinoma.
Tangjitgamol S; Warnnissorn M; Attakettaworn K; Puripat N
J Med Assoc Thai; 2013 Jan; 96(1):107-11. PubMed ID: 23720986
[TBL] [Abstract][Full Text] [Related]
17. The role of immunohistochemistry in differentiating between peritoneal mesothelioma and ovarian serous carcinoma.
Al-Rawi HJ; Ben-Ghashir NS
Saudi Med J; 2009 Apr; 30(4):571-4. PubMed ID: 19370292
[No Abstract] [Full Text] [Related]
18. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
19. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
20. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
Chapel DB; Husain AN; Krausz T; McGregor SM
Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
